We first came into contact with this probiotic ingredient when our client Prairie Naturals launched their BLIS K12® probiotic gum many years ago. Today, the oral probiotic market is fast growing, and one of our industry partners CK Ingredients has asked that we help get the word out on this unique supplement ingredient. A recent study published a month ago found some exciting results in children, helping to prevent recurring strep infections.
BLIS K12® is a rare strain of Streptococcus salivarius, a probiotic, which when taken orally (or as a lozenge) has some fantastic health benefits. In Canada, you can view our NPN on the raw material by clicking here (NPN 80063035). Health Canada has licensed this probiotic in adults for oral health (as a lozenge that is sucked on). It can help recolonize healthy oral bacteria in the mouth (such as after antibiotic treatment), and can even help reduce volatile sulfur compound levels that cause halitosis (bad breath). Perhaps more importantly, though, it has shown in adults to help reduce the incidence of strep infections of the throat/pharynx.
The recent study published last month in Therapeutics and Clinical Risk Management (Vol. 12) by Gregori et al (2016) found that when children prone to repeated strep infections received a daily dose of BLIS K12® over 3 months, the repeated infections diminished significantly. This continued for up to a year after the study was completed.
Any manufacturer interested in using BLIS K12® in one of their nutraceutical products should contact Michael Chernyak, CEO of CK Ingredients at 416-747-8434 (x222) or mchernyak[at]ckingredients.com.